131 related articles for article (PubMed ID: 38636950)
1. Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons with HIV Receiving Tenofovir Alafenamide and Emtricitabine-based Antiretroviral Therapy (QUANTI-TAF).
Coyle RP; Morrow M; Mann SC; Mainella V; Ellis SL; Schwab S; Coppinger C; Barker N; Ellison L; Zheng JH; Al Zuabi S; Alpert PE; Carnes TC; Buffkin DE; Chai PR; Bushman LR; Kiser JJ; MaWhinney S; Brooks KM; Anderson PL; Castillo-Mancilla JR
Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38636950
[TBL] [Abstract][Full Text] [Related]
2. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
3. Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence.
Morrow M; MaWhinney S; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR
AIDS; 2021 Oct; 35(12):1949-1956. PubMed ID: 34127580
[TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF.
Tran HT; Tsuchiya K; Kawashima A; Watanabe K; Hayashi Y; Ryu S; Hamada A; Gatanaga H; Oka S
Glob Health Med; 2023 Aug; 5(4):216-222. PubMed ID: 37655187
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078
[TBL] [Abstract][Full Text] [Related]
7. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Castillo-Mancilla J; Seifert S; Campbell K; Coleman S; McAllister K; Zheng JH; Gardner EM; Liu A; Glidden DV; Grant R; Hosek S; Wilson CM; Bushman LR; MaWhinney S; Anderson PL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6692-6697. PubMed ID: 27572401
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578
[TBL] [Abstract][Full Text] [Related]
9. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
[TBL] [Abstract][Full Text] [Related]
10. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
11. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR
J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768
[TBL] [Abstract][Full Text] [Related]
12. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.
Gandhi M; Glidden DV; Liu A; Anderson PL; Horng H; Defechereux P; Guanira JV; Grinsztejn B; Chariyalertsak S; Bekker LG; Grant RM;
J Infect Dis; 2015 Nov; 212(9):1402-6. PubMed ID: 25895984
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa.
Singh Y; Castillo-Mancilla J; Madimabe R; Jennings L; Ferraris CM; Robbins RN; Anderson PL; Remien RH; Orrell C
AIDS Res Ther; 2023 Sep; 20(1):67. PubMed ID: 37705102
[TBL] [Abstract][Full Text] [Related]
14. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Patients With HIV-1 Infection and Ongoing Substance Use Disorder: The BASE Study.
Havens JP; Bares SH; Lyden E; Podany AT; Scarsi KK; Fadul N; Swindells S
Open Forum Infect Dis; 2023 Mar; 10(3):ofad080. PubMed ID: 36910693
[TBL] [Abstract][Full Text] [Related]
17. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of tenofovir alafenamide, emtricitabine, and dolutegravir in a patient on peritoneal dialysis.
Massih SA; Atta MG; Thio CL; Tornheim JA; Fuchs EJ; Bakshi RP; Marzinke MA; Hendrix CW; Weld ED
AIDS Res Ther; 2024 May; 21(1):34. PubMed ID: 38773606
[TBL] [Abstract][Full Text] [Related]
19. Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots.
Saderup AM; Morrow M; Libby AM; Coyle RP; Coleman SS; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL; Castillo-Mancilla JR
Pharmacotherapy; 2021 Mar; 41(3):291-298. PubMed ID: 33594735
[TBL] [Abstract][Full Text] [Related]
20. Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy.
Dorward J; Govender K; Moodley P; Lessells R; Samsunder N; Sookrajh Y; Fanshawe TR; Turner PJ; Butler CC; Drain PK; Hayward GN; Garrett N
AIDS; 2024 Apr; 38(5):697-702. PubMed ID: 38126342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]